226 related articles for article (PubMed ID: 26243272)
1. Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM).
Demeure K; Fack F; Duriez E; Tiemann K; Bernard A; Golebiewska A; Bougnaud S; Bjerkvig R; Domon B; Niclou SP
Mol Cell Proteomics; 2016 Feb; 15(2):481-92. PubMed ID: 26243272
[TBL] [Abstract][Full Text] [Related]
2. The angiogenic switch leads to a metabolic shift in human glioblastoma.
Talasila KM; Røsland GV; Hagland HR; Eskilsson E; Flønes IH; Fritah S; Azuaje F; Atai N; Harter PN; Mittelbronn M; Andersen M; Joseph JV; Hossain JA; Vallar L; Noorden CJ; Niclou SP; Thorsen F; Tronstad KJ; Tzoulis C; Bjerkvig R; Miletic H
Neuro Oncol; 2017 Mar; 19(3):383-393. PubMed ID: 27591677
[TBL] [Abstract][Full Text] [Related]
3. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
[No Abstract] [Full Text] [Related]
5. Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma.
Sanzey M; Abdul Rahim SA; Oudin A; Dirkse A; Kaoma T; Vallar L; Herold-Mende C; Bjerkvig R; Golebiewska A; Niclou SP
PLoS One; 2015; 10(5):e0123544. PubMed ID: 25932951
[TBL] [Abstract][Full Text] [Related]
6. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme.
Qin Y; Takahashi M; Sheets K; Soto H; Tsui J; Pelargos P; Antonios JP; Kasahara N; Yang I; Prins RM; Braun J; Gordon LK; Wadehra M
J Neurooncol; 2017 Aug; 134(1):29-40. PubMed ID: 28597184
[TBL] [Abstract][Full Text] [Related]
7. Tenascin-C Orchestrates Glioblastoma Angiogenesis by Modulation of Pro- and Anti-angiogenic Signaling.
Rupp T; Langlois B; Koczorowska MM; Radwanska A; Sun Z; Hussenet T; Lefebvre O; Murdamoothoo D; Arnold C; Klein A; Biniossek ML; Hyenne V; Naudin E; Velazquez-Quesada I; Schilling O; Van Obberghen-Schilling E; Orend G
Cell Rep; 2016 Dec; 17(10):2607-2619. PubMed ID: 27926865
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
[TBL] [Abstract][Full Text] [Related]
10. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
11. LBH589 Inhibits Glioblastoma Growth and Angiogenesis Through Suppression of HIF-1α Expression.
Yao ZG; Li WH; Hua F; Cheng HX; Zhao MQ; Sun XC; Qin YJ; Li JM
J Neuropathol Exp Neurol; 2017 Dec; 76(12):1000-1007. PubMed ID: 29136455
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
[TBL] [Abstract][Full Text] [Related]
13. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.
Keunen O; Johansson M; Oudin A; Sanzey M; Rahim SA; Fack F; Thorsen F; Taxt T; Bartos M; Jirik R; Miletic H; Wang J; Stieber D; Stuhr L; Moen I; Rygh CB; Bjerkvig R; Niclou SP
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3749-54. PubMed ID: 21321221
[TBL] [Abstract][Full Text] [Related]
14. Loss of endothelial programmed cell death 10 activates glioblastoma cells and promotes tumor growth.
Zhu Y; Zhao K; Prinz A; Keyvani K; Lambertz N; Kreitschmann-Andermahr I; Lei T; Sure U
Neuro Oncol; 2016 Apr; 18(4):538-48. PubMed ID: 26254477
[TBL] [Abstract][Full Text] [Related]
15. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
16. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
17. MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2.
Sun J; Zheng G; Gu Z; Guo Z
J Neurooncol; 2015 May; 122(3):481-9. PubMed ID: 25939439
[TBL] [Abstract][Full Text] [Related]
18. Loss of cytoskeleton protein ADD3 promotes tumor growth and angiogenesis in glioblastoma multiforme.
Kiang KM; Zhang P; Li N; Zhu Z; Jin L; Leung GK
Cancer Lett; 2020 Apr; 474():118-126. PubMed ID: 31958485
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells.
Mughal AA; Grieg Z; Skjellegrind H; Fayzullin A; Lamkhannat M; Joel M; Ahmed MS; Murrell W; Vik-Mo EO; Langmoen IA; Stangeland B
Mol Cancer; 2015 Aug; 14():160. PubMed ID: 26292663
[TBL] [Abstract][Full Text] [Related]
20. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
